EP4340847A4 - Composition of mesalazine enteric tablet formulation - Google Patents
Composition of mesalazine enteric tablet formulationInfo
- Publication number
- EP4340847A4 EP4340847A4 EP21940969.5A EP21940969A EP4340847A4 EP 4340847 A4 EP4340847 A4 EP 4340847A4 EP 21940969 A EP21940969 A EP 21940969A EP 4340847 A4 EP4340847 A4 EP 4340847A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- tablet formulation
- enteric tablet
- mesalazine enteric
- mesalazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical group NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 title 1
- 229960004963 mesalazine Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000007916 tablet composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/005—Coating of tablets or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2021/050472 WO2022245307A1 (en) | 2021-05-21 | 2021-05-21 | Composition of mesalazine enteric tablet formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4340847A1 EP4340847A1 (en) | 2024-03-27 |
EP4340847A4 true EP4340847A4 (en) | 2024-07-17 |
Family
ID=84141571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21940969.5A Pending EP4340847A4 (en) | 2021-05-21 | 2021-05-21 | Composition of mesalazine enteric tablet formulation |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4340847A4 (en) |
WO (1) | WO2022245307A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021391823A1 (en) | 2020-12-03 | 2023-06-29 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
JP2024516108A (en) | 2021-04-07 | 2024-04-12 | バテル・メモリアル・インスティテュート | Rapid Design, Build, Test, and Learn Techniques for Identifying and Using Nonviral Carriers |
CN115957330A (en) * | 2022-12-16 | 2023-04-14 | 扬子江药业集团有限公司 | Enteric-coated layer, preparation method thereof and oral preparation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2187741A1 (en) * | 1994-04-22 | 1995-11-02 | Shunsuke Watanabe | Colon-specific drug release system |
US20120282333A1 (en) * | 2009-10-16 | 2012-11-08 | Ranbaxy Laboratories Limited | Delayed release pharmaceutical composition of mesalamine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2425826A1 (en) * | 2010-09-01 | 2012-03-07 | Disphar International B.V. | Mesalazine tablet having improved dissolution |
CN102048707A (en) * | 2010-11-29 | 2011-05-11 | 黑龙江天宏药业有限公司 | Mesalazine enteric-coated tablet and preparation method thereof |
JP6294457B2 (en) * | 2013-03-15 | 2018-03-14 | ワーナー チルコット カンパニー, エルエルシーWarner Chilcott Company, Llc | Mesalamine pharmaceutical composition comprising multiple dosing elements for reduced delivery variability |
-
2021
- 2021-05-21 WO PCT/TR2021/050472 patent/WO2022245307A1/en active Application Filing
- 2021-05-21 EP EP21940969.5A patent/EP4340847A4/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2187741A1 (en) * | 1994-04-22 | 1995-11-02 | Shunsuke Watanabe | Colon-specific drug release system |
US20120282333A1 (en) * | 2009-10-16 | 2012-11-08 | Ranbaxy Laboratories Limited | Delayed release pharmaceutical composition of mesalamine |
Non-Patent Citations (2)
Title |
---|
ANONYMOUS: "Summary of Product Characteristics (SmPC) for Salofalk 500 mg gastro-resistant tablets", MEDICINES.ORG, 1 January 2018 (2018-01-01), pages 1 - 5, XP055534701, Retrieved from the Internet <URL:https://www.medicines.org.uk/emc/product/5785/smpc/print> [retrieved on 20181214] * |
See also references of WO2022245307A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP4340847A1 (en) | 2024-03-27 |
WO2022245307A1 (en) | 2022-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4340847A4 (en) | Composition of mesalazine enteric tablet formulation | |
IL279464A (en) | Pharmaceutical formulation of odevixibat | |
IL292682A (en) | Oral formulation of x842 | |
IL304354A (en) | Solid tablet dosage form of ridinilazole | |
EP3532052A4 (en) | Design and composition of cell-stabilized pharmaceutical formulations | |
GB202010230D0 (en) | Pharmaceutical formulation | |
IL304159A (en) | Composition of bl-8040 | |
IL297081A (en) | Pharmaceutical formulation | |
EP4062913C0 (en) | Solid oral formulation of utidelone | |
IL253824A0 (en) | Pharmaceutical formulations of c1 esterase inhibitor | |
IL307482B2 (en) | Application of hair-coloring compositions | |
EP4251153A4 (en) | Lyophilized formulations of tegavivint | |
IL271875A (en) | Application of totarol and pharmaceutical composition containing totarol | |
IL265662A (en) | Pharmaceutical compositions of 5-ht6 antagonist | |
HK1244224B (en) | Pharmaceutical composition of mek inhibitor and preparation method thereof | |
EP3466409C0 (en) | Self-emulsifying compositions of weakly ionizable or non-ionizable active pharmaceutical ingredients | |
IL253788A0 (en) | Pharmaceutical formulation of racecadotril | |
IL312073A (en) | Pharmaceutical compositions of efruxifermin | |
IL314824A (en) | Combination formulation of cedazuridine | |
IL310652A (en) | Formulations of radiprodil | |
ZA202205263B (en) | Solid pharmaceutical forms of perampanel | |
ZA202002086B (en) | Alcohol-resistant oral pharmaceutical compositions of lorazepam | |
EP4208468A4 (en) | Radiolabeling and formulation for scale up of 64cu-dotatate | |
IL297080A (en) | Pharmaceutical formulation | |
GB202100526D0 (en) | Pharmaceutical formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20231101 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20240618 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/28 20060101ALI20240612BHEP Ipc: A61K 9/16 20060101ALI20240612BHEP Ipc: A61P 1/04 20060101ALI20240612BHEP Ipc: A61J 3/00 20060101ALI20240612BHEP Ipc: A61K 31/606 20060101AFI20240612BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |